Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veerle C M Geurts

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Chemotherapy|May 25, 2025
Carnitine Levels Decrease during Oxaliplatin Infusion: A Pilot StudyLianne P W van Geffen, Floortje Mols, Veerle C M Geurts, et al.
Cell Reports. Medicine|December 17, 2025
CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancerAaron Y Lin, Olga I Isaeva, Teoman Deger, et al.
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
Nature|December 5, 2024
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapyLaura Bornes, Lennart J van Winden, Veerle C M Geurts, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Chemotherapy|May 25, 2025
Carnitine Levels Decrease during Oxaliplatin Infusion: A Pilot StudyLianne P W van Geffen, Floortje Mols, Veerle C M Geurts, et al.
Cell Reports. Medicine|December 17, 2025
CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancerAaron Y Lin, Olga I Isaeva, Teoman Deger, et al.
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
Nature|December 5, 2024
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapyLaura Bornes, Lennart J van Winden, Veerle C M Geurts, et al.
Pageof 1